AbCellera Biologics Inc. ABCL
11.11 USD -0.01 (-0.09%)
As ofNov 17, 2026, 12:19 PM EST
10.81 Day range 11.40
2.75 52-week range 15.02
- YTD
- +224.85%
- 1 year
- +208.61%
News
marketbeat.com AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot flash treatment ABCL635 into late-stage studies, with a registrational trial potentially starting around the middle of…benzinga.com Piper Sandler Maintains Overweight on AbCellera Biologics, Raises Price Target to $20 Piper Sandler analyst Allison Bratzel maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $12 to $20.
seekingalpha.com AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript AbCellera Biologics Inc. ( ABCL ) Stifel 2026 Healthcare Conference 2026 November 10, 2026 7:00 PM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Conference Call Participants…
zacks.com Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? Here is how AbCellera Biologics Inc. (ABCL) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
marketbeat.com AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot-flash treatment ABCL635 into late-stage development next year after a midstage study produced stronger-than-expected…benzinga.com StoneX Maintains Buy on AbCellera Biologics, Raises Price Target to $15 StoneX analyst Robert Wasserman maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $11 to $15.
benzinga.com Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $14 Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $9 to $14.
benzinga.com AbCellera Biologics Q3 2026 Earnings Call Transcript AbCellera Biologics (NASDAQ:ABCL) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com AbCellera Biologics Q3 EPS $(0.13) Beats $(0.16) Estimate, Sales $10.639M Beat $8.416M Estimate AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 31.58 percent increase over losses of…
